5Fontaine KR,Hero M,Harrigan EP,et al.Estimating the conse-quences ofanti-psychotic inducedweightgain on health andmortali-ty rate[J].PsychiatryRes,2001,101 (3):277-288.
6Newcomer JW.Second-generation (atypical)antipsychotics andmet-abolic effects:a comprehensive literature review[J].CNS Drugs,2005,19(Suppl 1):1-93.
7Minet-RinguetJ,Even PC,Valet P,et al.Alterationsof lipidmetabo-lism and gene expression in rat adipocytes during chronic olanzapinetreatment[J].MolPsychiatry,2007,12(6):562-571.
8Spurling RD,Lamberti JS,Olsen D,et al.Changes in metabolic pa-rameterswith switching to aripiprazole from another second-genera-tion antipsychotic:a retrospective chart review[J].J Clin Psychiatry,2007,68(3):406-409.
9Kornegay CJ,Vasilakis-Scaramozza C,Jick L.Incident diabetes associate with antipsychotic use in the United Kingdom general practice research database[J].J Clin Psychiatry,2002,63(9):758-762.
8Hagg MD,Joelsson MD,Mjorndal MD,et al.Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventioned depot newrpleptic medications[J].J Clin Psychiatry,1998,59:294
